Skip to main content

Table 1 Baseline characteristics

From: Clinical trials of artesunate plus sulfadoxine-pyrimethamine for Plasmodium falciparum malaria in Afghanistan: maintained efficacy a decade after introduction

Parameter

Study

Trial 1

Trial 2

Trial 3

DP

AS + SP

AS + SP

AS + SP

Year

2007–2010

2007–2010

2010–2011

2012–2014

No. of patients

59

61

100

83

Location (%)

 Jalalabad

41 (69)

42 (69)

100 (100)

–

 Takhar

6 (10)

5 (8)

–

–

 Faryab

1 (2)

3 (5)

–

–

 Kunar

11 (19)

11 (18)

–

83 (100)

Age (years) (median, range)

11 (2–52)

13 (1–70)

15.5 (3–55)

18 (1–74)

Gender male/female (ratio)

43/16 (2.7)

35/26 (1.3)

60/40 (1.5)

49/34 (1.4)

Body weight (kg) (median, range)

31 (8–87)

35 (7.5-85)

50 (10-72)

49 (10–75)

Median parasitaemia/µl (range)

6760 (1220–90,000)

7200 (900–62,160)

4680 (1000–95,000)

3220 (500–59,520)

No. of patients with gametocytes (%)

13 (22)

29 (48)

19 (19)

42 (51)

Mean axillary temp (°C) ± SD

37.9 ± 1.1

37.9 ± 1.0

38.4 ± 0.8

38.4 ± 0.9

Mean hemoglobin (g/dl) ± SD

11.2 ± 1.3

11.2 ± 1.4

11.50 ± 0.9

11.6 ± 1.9

Mean total drug dose (mg/kg) ± SD

 Artemisinin derivative

6.7 ± 1.2 (DHA)

10.42 ± 1.9 (AS)

10.5 ± 2.0 (AS)

10.5 ± 2.4 (AS)

 Partner drug

53.9 ± 9.3 (PIP)

27.35 ± 11.9 (SUL)

26.8 ± 5.0 (SUL)

27.3 ± 6.1 (SUL)